Results 11 to 20 of about 377,889 (137)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. [PDF]

PLoS ONE, 2015
BackgroundHuman papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV18 through the generation of type-specific neutralizing antibodies raised against virus-like particles (VLP) representing these genotypes.
Anna Godi, Sara L Bissett, Elizabeth Miller, Simon Beddows   +3 more
doaj   +3 more sources

Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females [PDF]

Human Vaccines & Immunotherapeutics, 2017
One hundred and ninety eight females aged 12–15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine ...
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller   +3 more
doaj   +2 more sources

Corrigendum: Gardasil® as adjunctive therapy for respiratory papillomatosis at Red Cross Children’s Hospital, Cape Town [PDF]

Journal of the Colleges of Medicine of South Africa
No abstract available.
Shavina Frank, Jessica K. McGuire, Fiona Kabagenyi, Vincent Pretorius, Shazia Peer   +4 more
doaj   +2 more sources

AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells [PDF]

Frontiers in Immunology
IntroductionThe Gardasil-4® vaccine targets HPV types 6, 11, 16 and 18 and is formulated with amorphous alum. Cervarix® targets HPV types 16 and 18 using AS04 (Al(OH)3 + TLR4 agonist MPL) to enhance immune response.
Valentino D’Onofrio, Ana Carolina Santana, Ana Carolina Santana, Marthe Pauwels, Marthe Pauwels, Gwenn Waerlop, Anthony Willems, Fien De Boever, Martin Müller, Peter Sehr, Tim Waterboer, Isabel Leroux-Roels, Ashish A. Sharma, Ashish A. Sharma, Rafick Pierre Sékaly, Rafick Pierre Sékaly, Geert Leroux-Roels   +16 more
doaj   +2 more sources

Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded [PDF]

Infectious Agents and Cancer
Several high-risk types of human papillomaviruses (HPVs) are associated with cervical cancer and other malignancies. Despite the tremendous success of marketed prophylactic HPV vaccines for the past 18 years, cervical cancer remains a significant global ...
Sogand Amiri, Shiva Rasekh, Seyed Mohammad Iman Moezzi, Nadia Seifi, Seyed Amirreza Fatemi, Shirin Fathi, Ashkan Bagheri, Manica Negahdaripour   +7 more
doaj   +2 more sources

Syndemic Synergy of HPV, HIV, and HSV-2 for Oncogenic HPV Replication in Female Sex Workers [PDF]

Tropical Medicine and Infectious Disease
Background: Female sex workers (FSWs) in sub-Saharan Africa bear a disproportionate burden of sexually transmitted infections, including HIV, high-risk HPV (HR-HPV), and herpes simplex virus type 2 (HSV-2).
Jonathan Muwonga Tukisadila, Ralph-Sydney Mboumba Bouassa, Serge Tonen-Wolyec, Hugues Loemba, Jeremie Muwonga, Laurent Belec   +5 more
doaj   +2 more sources

Chlamydia trachomatis Infection and Its Association with Human Papillomavirus Among Adolescent Girls and Young Women of Eastern Cape, South Africa [PDF]

Epidemiologia
Background/Objectives: Adolescent girls and young women (AGYW) have a high burden of sexually transmitted infections (STIs). This study examined the prevalence of Chlamydia trachomatis, its association with human papillomavirus (HPV), and other ...
Olufunmilayo O. Akapo, Zizipho Z. A. Mbulawa   +1 more
doaj   +2 more sources

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial [PDF]

npj Vaccines
Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time. One driver of such responses is memory B-cells (MBCs), primed during initial HPV-vaccine exposure.
Rebecca Wiggins, Kathy J. Baisley, Jackton Indangasi, John Changalucha, Helen Ashwin, Najmeeyah Brown, Hilary S. Whitworth, David Joakim, Philippe Mayaud, Ramadhan Hashim, Caroline Maxwell, Paul Mutani, Beatrice Kamala, Brett Lowe, Ligia Pinto, Troy Kemp, Silvia deSanjosé, Saidi Kapiga, Richard J. Hayes, Deborah Watson-Jones, Charles J. Lacey   +20 more
doaj   +2 more sources

A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine [PDF]

Vaccines
Background: Cervical cancer is associated with persistent infection of high-risk human papillomaviruses (HPVs). Prophylactic HPV vaccines have been recommended and have significant efficacy in preventing cervical cancer.
Dan Xu, Jia-Dai Li, Jiao An, Xin-Xing Ma, Xiao-Liang Wang, Zheng Zhou, Hai-Ping Liu, Mei-Jun Diao, Yuan-Xiang Jiang, Ling-Yun Zhou, Xin Tong, Chen-Liang Zhou   +11 more
doaj   +2 more sources

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection [PDF]

Human Vaccines & Immunotherapeutics, 2018
Human papillomavirus (HPV) infection is a frequent cause of malignant and non-malignant disease, in particular among persons with HIV. HPV serotype-specific anti L1 antibodies protect against HPV infection but little is known about prophylactic HPV ...
Maria Zurek Munk-Madsen, Lars Toft, Tina Kube, Rolf Richter, Lars Ostergaard, Ole S. Søgaard, Martin Tolstrup, Andreas M. Kaufmann   +7 more
doaj   +2 more sources